Trial reportNature medicine2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
2 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 202 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
202citing papers in PubMed, 6 pooled it
32.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
NCT06384573 phase3active not recruitingnot on this mapstarted 2024, after this paper: background citation
The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Amyloid Removal Trial (ART): A Phase IIIb/IV Open-Label Study of Lecanemab to Evaluate Prevention and Progression of Dominantly Inherited Alzheimer's Disease
Who cites it
202 citing papers in PubMed, 6 syntheses or guidelines pooled it, 354 citations in OpenAlex.
- Incidence, severity, and associated risk factors for amyloid-related imaging abnormalities in anti-amyloid monoclonal antibody therapy for early Alzheimer's disease: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease.The Cochrane database of systematic reviews · 2026Pooled it
- Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Pooled it
- Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Pharmacologic and Nutritional Interventions for Early Alzheimer's Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.Journal of Alzheimer's disease : JAD · 2024Pooled it
- Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis.Annals of family medicinePooled it
- The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial.Nature medicine · 2026Trial
- Etalanetug (E2814) in dominantly inherited Alzheimer's disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairment.Alzheimer's research & therapy · 2026Trial
- The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Trial
- Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Trial
- Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease.Acta neuropathologica · 2025Trial
- Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.The Lancet. Neurology · 2025Trial
- Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.The journal of prevention of Alzheimer's disease · 2025Trial
- Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer's Disease: Secondary Analyses from the A4 Study.The journal of prevention of Alzheimer's disease · 2024Trial
- Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?Neurology · 2023Trial
- Augmenting randomized clinical trial data with historical control data: Precision medicine applications.Journal of the National Cancer Institute · 2023Trial
- Anatomy of a Setback: A Taxonomy of Clinical Trial Failures in Alzheimer's Disease and Strategic Lessons for the Future.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Statistical models for Alzheimer's disease clinical trials: Lessons learned from the DIAN-TU Platform Trial.Journal of Alzheimer's disease : JAD · 2026Article
- Alzheimer's disease: from molecular pathways to therapies.Molecular biomedicine · 2026Review
- Dietary Bioactives in Alzheimer's Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies.Nutrients · 2026Review
142 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
66 authors at 20 institutions in 8 countries.
Stephen Salloway *Warren Alpert Medical School of Brown University, Providence, RI, USA.ORCID http://orcid.org/0000-0002-2631-0942
Martin Farlow *Indiana University School of Medicine, Indianapolis, IN, USA.
Eric McDadeWashington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-6764-3866
David B CliffordWashington University School of Medicine, St. Louis, MO, USA.
Guoqiao WangWashington University School of Medicine, St. Louis, MO, USA.
Jorge J Llibre-GuerraWashington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-2137-7750
Janice M HitchcockHitchcock Regulatory Consulting, Inc, Fishers, IN, USA.
Susan L MillsWashington University School of Medicine, St. Louis, MO, USA.
Anna M SantacruzWashington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-4110-6472
Andrew J AschenbrennerWashington University School of Medicine, St. Louis, MO, USA.
Jason HassenstabWashington University School of Medicine, St. Louis, MO, USA.
Tammie L S BenzingerWashington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-8114-0552
Brian A GordonWashington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-2109-2955
Anne M FaganWashington University School of Medicine, St. Louis, MO, USA.
Kelley A CoalierWashington University School of Medicine, St. Louis, MO, USA.
Carlos CruchagaWashington University School of Medicine, St. Louis, MO, USA.
Alison A GoateIcahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-0576-2472
Richard J PerrinWashington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-3443-7716
Chengjie XiongWashington University School of Medicine, St. Louis, MO, USA.
Yan LiWashington University School of Medicine, St. Louis, MO, USA.
John C MorrisWashington University School of Medicine, St. Louis, MO, USA.
B Joy SniderWashington University School of Medicine, St. Louis, MO, USA.
Catherine MummeryUniversity College London, London, UK.ORCID http://orcid.org/0000-0002-6739-0803
G Mustafa SurtiWarren Alpert Medical School of Brown University, Providence, RI, USA.
Didier HannequinCentre Hospitalier Universitaire de Rouen, Rouen, France.
David WallonCentre Hospitalier Universitaire de Rouen, Rouen, France.
Sarah B BermanUniversity of Pittsburgh Medical Center, Pittsburgh, PA, USA.
James J LahEmory University Medical Center, Atlanta, GA, USA.
Ivonne Z Jimenez-VelazquezUniversity of Puerto Rico School of Medicine, San Juan, Puerto Rico.
Erik D RobersonUniversity of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.ORCID http://orcid.org/0000-0002-1810-9763
Christopher H van DyckYale University School of Medicine, New Haven, CT, USA.
Lawrence S HonigColumbia University Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-9703-2265
Raquel Sánchez-ValleHospital Clínic i Provincial de Barcelona, August Pi i Sunyer Biomedical Research Institute-Universitat de Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0001-7750-896X
William S BrooksNeuroscience Research Australia, University of New South Wales Medicine, Randwick, New South Wales, Australia.ORCID http://orcid.org/0000-0001-8603-4233
Serge GauthierMcGill Center for Studies in Aging, McGill University, Montreal, Quebec, Canada.
Douglas R GalaskoUniversity of California San Diego, San Diego, CA, USA.
Colin L MastersUniversity of Melbourne, Melbourne, Victoria, Australia.
Jared R BroschIndiana University School of Medicine, Indianapolis, IN, USA.
Ging-Yuek Robin HsiungUniversity of British Columbia, Vancouver, British Columbia, Canada.
Suman JayadevUniversity of Washington School of Medicine, Seattle, WA, USA.
Maité FormaglioHospices Civils de Lyon, Lyons, France.
Mario MasellisSunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Roger ClarnetteAustralian Alzheimer's Research Foundation, University of Western Australia, Perth, Western Australia, Australia.
Jérémie ParienteCentre Hospitalier Universitaire de Toulouse, Toulouse, France.
Bruno DuboisNeurological Institute, Salpetriere University Hospital, Paris, France.
Florence PasquierCentre Hospitalier Régional Universitaire de Lille, Lille, France.ORCID http://orcid.org/0000-0001-9880-9788
Clifford R JackMayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-7916-622X
Robert KoeppeUniversity of Michigan, Ann Arbor, MI, USA.
Peter J SnyderUniversity of Rhode Island, Kingston, RI, USA.ORCID http://orcid.org/0000-0003-0555-4654
Paul S AisenKeck School of Medicine, University of Southern California, San Diego, CA, USA.
Ronald G ThomasUniversity of California San Diego, San Diego, CA, USA.ORCID http://orcid.org/0000-0003-1686-4965
Scott M BerryBerry Consultants, LLC, Austin, TX, USA.
Barbara A WendelbergerBerry Consultants, LLC, Austin, TX, USA.ORCID http://orcid.org/0000-0003-4426-9602
Scott W AndersenEli Lilly and Company, Indianapolis, IN, USA.
Karen C HoldridgeEli Lilly and Company, Indianapolis, IN, USA.
Mark A MintunEli Lilly and Company, Indianapolis, IN, USA.
Roy YaariEli Lilly and Company, Indianapolis, IN, USA.
John R SimsEli Lilly and Company, Indianapolis, IN, USA.
Monika BaudlerF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Paul DelmarF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Rachelle S DoodyF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Paulo FontouraF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Caroline GiacobinoF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Geoffrey A KerchnerF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Randall J BatemanWashington University School of Medicine, St. Louis, MO, USA. batemanr@wustl.edu.ORCID http://orcid.org/0000-0002-7729-1702
Dominantly Inherited Alzheimer Network–Trials Unit
Washington University in St. Louis · USRoche (Switzerland) · CHEli Lilly (United States) · USBerry & Associates (United States) · USBrown University · USCentre Hospitalier Universitaire de Rouen · FRCentre Hospitalier Universitaire de Toulouse · FRHospices Civils de Lyon · FRIndiana University School of MedicineUniversity of California San Diego · USYale University · USCentre Hospitalier Universitaire de Lille · FRColumbia University Irving Medical Center · USDartmouth–Hitchcock Medical Center · USEmory University · USIcahn School of Medicine at Mount Sinai · USMayo Clinic in Arizona · USMcGill University · CASunnybrook Health Science Centre · CAThe University of Melbourne · AU
Funding
Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MICHAEL W WEINER · 2016 to 2026
$226.7MSmartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5MImaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9MThe natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5MDIAN-TU Next Generation Prevention Trial - Data Request Management SupplementR01AG053267 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2017 to 2023
$34.9MYale Alzheimer Disease Research CenterP30AG066508 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER, CHRISTOPHER H VAN DYCK · 2020 to 2026
$30.2MResearch Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI DAVID M. HOLTZMAN · 2020 to 2026
$28.7MDominantly Inherited Alzheimer's Network Trials Unit - Adaptive Prevention TrialR01AG046179 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2014 to 2019
$26.6MDominantly Inherited Alzheimer NetworkUF1AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2014 to 2017
$21.6MDOMINANTLY INHERITED ALZHEIMER NETWORK TRIAL: AN OPPORTUNITY TO PREVENT DEMENTIAU01AG042791 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2013 to 2018
$8.9MPURCHASE OF A SIEMENS NEXT GENERATION PET/CTS10OD025214 · OD · WASHINGTON UNIVERSITY · PI WOODARD, PAMELA K · 2018 to 2018
$2.0MNIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066508NIA NIH HHS R01 AG046179NIA NIH HHS R01 AG053267NIA NIH HHS U01 AG042791NIA NIH HHS U19 AG024904NIA NIH HHS U19 AG032438NIA NIH HHS UF1 AG032438NIH HHS S10 OD025214U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) R01AG046179, R01AG053267-S1U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) U01AG042791U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) U01AG042791-S1U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) U19AG032438
Abstract
Dominantly inherited Alzheimer's disease (DIAD) causes predictable biological changes decades before the onset of clinical symptoms, enabling testing of interventions in the asymptomatic and symptomatic stages to delay or slow disease progression. We conducted a randomized, placebo-controlled, multi-arm trial of gantenerumab or solanezumab in participants with DIAD across asymptomatic and symptomatic disease stages. Mutation carriers were assigned 3:1 to either drug or placebo and received treatment for 4-7 years. The primary outcome was a cognitive end point; secondary outcomes included clinical, cognitive, imaging and fluid biomarker measures. Fifty-two participants carrying a mutation were assigned to receive gantenerumab, 52 solanezumab and 40 placebo. Both drugs engaged their Aβ targets but neither demonstrated a beneficial effect on cognitive measures compared to controls. The solanezumab-treated group showed a greater cognitive decline on some measures and did not show benefits on downstream biomarkers. Gantenerumab significantly reduced amyloid plaques, cerebrospinal fluid total tau, and phospho-tau181 and attenuated increases of neurofilament light chain. Amyloid-related imaging abnormalities edema was observed in 19.2% (3 out of 11 were mildly symptomatic) of the gantenerumab group, 2.5% of the placebo group and 0% of the solanezumab group. Gantenerumab and solanezumab did not slow cognitive decline in symptomatic DIAD. The asymptomatic groups showed no cognitive decline; symptomatic participants had declined before reaching the target doses.
Indexed as
AdultAlzheimer DiseaseAmyloid beta-PeptidesAntibodies, Monoclonal, HumanizedBiomarkersDisease ProgressionDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedPlacebosAmyloid beta-PeptidesAntibodies, Monoclonal, HumanizedBiomarkersgantenerumabPlacebossolanezumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05269394ClinicalTrials.gov
NCT06384573ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.